Spike Identification Nanobody Panel for SARS-CoV-2 Vaccine Manufacturing
The goal of the 12-month NIIMBL project is to generate a panel of RBD-specific antibodies (“nanobodies”) that can be used for identity tests in the manufacture of SARS-CoV-2 subunit vaccines.
Categories
Vaccines
Assays
Process control
Industry Need
From the perspective of Chemistry, Manufacturing, and Controls (CMC), COVID-19 vaccines face challenges due to the large number of SARS-CoV-2 variants of concern (VoCs) that have emerged.
Specifically, reagents for analytical assays must discriminate among the closely related vaccine antigens like recombinant receptor-binding domain (RBD) subunits.
Solution
MassBiologics and the Wadsworth Center teamed up to generate a panel of RBD-specific antibodies (“nanobodies” or VHHs) that can be used for identity tests in the manufacture of SARS-CoV-2 subunit vaccines.
MassBiologics used yeast-display technologies to identify nanobodies specific for each RBD VoC, while Wadsworth Center evaluated the nanobodies’ suitability to function in mock identity tests with drug substances and drug products.
Outputs/Deliverables
• GLP-grade quality SARS-CoV-2 RBD protein antigens from wild type, Beta, Delta, and Omicron variants were produced and purified at milligram quantities.
• A panel of VoC-specific VHH-IgG antibodies against SARS-CoV-2 RBD spike protein were identified and characterized for binding affinity (ELISA, BLI), SARS-CoV-2 neutralization, and epitope class.
• Developed SOPs for RBD and RBD adsorbed binding assays
Additional Project Information (Members Only)
Login to the NIIMBL member portal to access more, including: